Quantcast

Latest Amgen Stories

2014-04-23 12:29:37

New Entity YL Biologics to focus on clinical development and commercialization of Biosimilars for Japan MUMBAI and BALTIMORE, April 23, 2014 /PRNewswire/ -- Pharma Major, Lupin Limited (Lupin) announced today that it has entered into a strategic joint venture agreement with Toyama based Japanese pharmaceuticals company, Yoshindo Inc. (Yoshindo) to create a new entity, YL Biologics (YLB). YLB will be jointly managed by both partners and will be responsible for conducting...

2014-04-18 08:22:04

PARSIPPANY, N.J., April 18, 2014 /PRNewswire/ -- Daiichi Sankyo, Inc. announced today that Ken Keller will join the company as President of its Commercial operations in the United States starting May 1, 2014. In his role, Mr. Keller will be responsible for leading marketing, sales, medical affairs and supply chain operations for Daiichi Sankyo in the U.S. "We are very pleased to welcome Ken Keller into the Daiichi Sankyo family," said Joji Nakayama, President and CEO of Daiichi...

2014-04-17 16:27:14

THOUSAND OAKS, Calif., April 17, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will report its first quarter financial results on Tuesday, April 22, 2014, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2:15 p.m. PDT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team. Live...

2014-04-11 08:24:38

SANTA MONICA, Calif., April 11, 2014 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced the appointment of Jonathan M. Peacock, former Chief Financial Officer of Amgen, to the Company's Board of Directors. Mr. Peacock's appointment is effective immediately, bringing the number of Kite's directors to eight. Arie Belldegrun,...

2014-04-04 08:25:45

THOUSAND OAKS, Calif., April 4, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced top-line results from the primary overall survival (OS) analysis of a Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to treatment with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF). Results showed that, while the primary end point of durable response...

2014-03-30 08:20:05

Data From Two Separate Phase 3 Studies of Evolocumab (AMG 145), a PCSK9 Inhibitor, Presented in Late-Breaking Clinical Trials Session at ACC.14 - Data Add to the Three Pivotal Studies Presented Yesterday THOUSAND OAKS, Calif., March 30, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new detailed data from two Phase 3 pivotal studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a statistically significant...

2014-03-29 16:20:11

Data From Three Separate Phase 3 Studies of Evolocumab (AMG 145), a PCSK9 Inhibitor, Presented as Featured Clinical Research at ACC.14 THOUSAND OAKS, Calif., March 29, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new detailed data from three Phase 3 studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a statistically significant reduction of 55-66 percent in low-density lipoprotein cholesterol (LDL-C)...

2014-03-28 12:26:15

DUBLIN, March 28, 2014 /PRNewswire/ -- Dublin - Research and Markets ( http://www.researchandmarkets.com/research/8zbxmj/investigation) has announced the addition of the "Investigation Report on China Epoetin Alfa Market, 2009-2018" [http://www.researchandmarkets.com/research/8zbxmj/investigation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Epoetin alfa refers to erythropoietin (EPO), a hormone-like substance secreted by...

2014-03-28 08:26:16

Carl Adams Promoted to Chief Financial Officer and Craig Rostamian Joins as Vice President of Finance LOS ANGELES, March 28, 2014 /PRNewswire/ -- NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch(TM) eTNS(TM) System for the treatment of neurological and neuropsychiatric disorders, announced the promotion of Carl Adams to Chief Financial Officer (CFO) and the appointment of Craig Rostamian as Vice President...

2014-03-27 12:31:03

LONDON, March 27, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Global and China Monoclonal Antibody Industry Report, 2013-2017 Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the market size of monoclonal antibody agents grew at a CAGR of 13%, far higher than the overall growth rate of...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related